Clinical Pharmacology & Biopharmaceutics
Open 91桃色
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open 91桃色 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open 91桃色 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 1089
Indexed In
- CAS Source Index (CASSI)
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
BP-C1 in treatment of metastatic breast cancer: A randomised, double blinded and placebo controlled clinical study
3rd International Conference on Clinical Pharmacy
Stig Larsen
Norwegian University of Life Science, Norway
Keynote: Clin Pharmacol Biopharm
DOI:
Abstract
Aim: The aim was to compare the efficacy and tolerability of a new benzene-poly-carboxylic acids complex with cisdiammineplatium (II) (BP-C1) versus equal looking placebo in treatment of metastatic breast cancer patients. Material & Methods: A randomized, double blind, placebo controlled multi-center study was performed with semi-cross-over design. Patients allocated to placebo switches to BP-C1 after 32 days of treatment. Thirty patients were given daily intramuscular injection of 0.035 mg/kg bw BP-C1 or placebo in 32 days. Biochemistry, hematology, NCI Bethesda (CTC-NCI), EORTC QOL-C30 & BR23 recorded at screening and after every 16 days of treatment. CT performed at screening and every 32nd day. Results: The sum of target lesions increased 2.4% in the BP-C1 group and 14.3% in placebo. The increase in the placebo group was significant (p=0.013) but not in BP-C1. The difference between the group was significant in favor of BP-C1 (p=0.04). Significant difference (p=0.026) in favor of BP-C1 regarding RECIST classification. CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group, but significantly in placebo (p=0.05). 芒�?�?Breast cancer related pain and discomfort芒�?聺 and 芒�?�?Breast cancer treatment problem last week芒�?聺 were significantly reduced (p=0.02) in the BP-C1 group and slightly increased in placebo. Significant difference in favor of BP-C1 (p=0.05). 芒�?�?Breast cancer treatment problem last week芒�?聺 was significantly reduced in the BP-C1 group (p=0.02) and slightly increased in placebo. 芒�?�?Breast cancer related pain and discomfort芒�?聺. Conclusion: BP-C1 reduces the cancer growth, is well tolerated, improves quality-of-life and has few mainly mild AE in patients suffering from stage IV MBC.Biography
Stig Larsen has completed his DSc in Clinical Research Methodology at Ullevål Hospital, Oslo University, Norway. He is Professor at the Norwegian University of Life Science and has published more than 300 papers in international medical and clinical research methodological journals.
Email: stig.larsen@nmbu.no
